Patient-reported impact of symptoms in Huntington disease
- 12 May 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (19) , e2045-e2053
Abstract
Objective To determine the frequency and relative importance of symptoms experienced by adults with Huntington disease (HD) and to identify factors associated with a higher disease burden. Methods We performed 40 qualitative interviews (n = 20 with HD, n = 20 caregivers) and analyzed 2,082 quotes regarding the symptomatic burden of HD. We subsequently performed a cross-sectional study with 389 participants (n = 156 with HD [60 of whom were prodromal], n = 233 caregivers) to assess the prevalence and relative importance (scale 0–4) of 216 symptoms and 15 symptomatic themes in HD. Cross-correlation analysis was performed based on sex, disease duration, age, number of CAG repeats, disease burden, Total Functional Capacity score, employment status, disease status, and ambulatory status. Results The symptomatic themes with the highest prevalence in HD were emotional issues (83.0%), fatigue (82.5%), and difficulty thinking (77.0%). The symptomatic themes with the highest relative importance to participants were difficulty thinking (1.91), impaired sleep or daytime sleepiness (1.90), and emotional issues (1.81). High Total Functional Capacity scores, being employed, and having prodromal HD were associated with a lower prevalence of symptomatic themes. Despite reporting no clinical features of the disease, prodromal individuals demonstrated high rates of emotional issues (71.2%) and fatigue (69.5%). There was concordance between the prevalence of symptoms reported by manifest individuals and caregivers. Conclusions Many symptomatic themes affect the lives of those with HD. These themes have a variable level of importance to the HD population and are identified both by those with HD and by their caregivers.Keywords
This publication has 20 references indexed in Scilit:
- Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA)Neurology, 2018
- Motor, cognitive, and functional declines contribute to a single progressive factor in early HDNeurology, 2017
- Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2)Neurology, 2015
- Quality-of-life in Charcot–Marie–Tooth disease: The patient’s perspectiveNeuromuscular Disorders, 2014
- Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)Neurology, 2012
- Huntington's disease: from molecular pathogenesis to clinical treatmentThe Lancet Neurology, 2011
- The Clinical and Genetic Features of Huntington DiseaseJournal of Geriatric Psychiatry and Neurology, 2010
- A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington DiseaseArchives of Neurology, 2010
- Trinucleotide repeat length and progression of illness in Huntington's disease.Journal of Medical Genetics, 1994
- A polymorphic DNA marker genetically linked to Huntington's diseaseNature, 1983